Ligand Pharmaceuticals, Inc.
http://www.ligand.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ligand Pharmaceuticals, Inc.
No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
Merck & Co. Seeds Neuroscience Expansion With Caraway Buy
The drug maker will spend up to $610m to acquire Caraway, with a lead product candidate targeting TRPML1, a pathway implicated in a number of neurodegenerative diseases.
Ovid Looks To Epilepsy – And Beyond – For Candidate OV350
Ovid anticipates its deal to sell part of its interest in soticlestat milestones and royalties to Ligand will take it through 2026, while it looks to develop its KCC2-targeting OV350 for psychiatric disorders.
Finance Watch: Aiolos Launches With $245m Series A; OrbiMed’s New Funds Total $4.3bn
Private Company Edition: Quarter-over-quarter increases in venture capital have been bolstered by fewer but larger rounds, like the recent $245m series A for Aiolos. Also, OrbiMed raised $4.3bn across three new VC funds, Rampart completed an $85m series A and Atom Bioscience raised an $83m series D.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Ab Initio Biotherapeutics
- Crystal Bioscience, Inc.
- CyDex Pharmaceuticals, Inc.
- Icagen Pharmaceuticals, Inc.
- Metabasis Therapeutics, Inc.
- Neurogen Corporation
- Pharmacopeia, Inc.
- Pfenex Inc.
- Verrow Pharmaceuticals, Inc.
- Vernalis Group plc
- Cita NeuroPharmaceuticals
- Taurus Biosciences LLC
- xCella Biosciences, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice